Latest / Stock Movers / Intel Rises, Mission Produce Drops, Tango Therapeutics Surges
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
- 0:08Speaker 2: The Stock Mover's Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
- 0:17Speaker 3: I'm Carol Master along with Tim Centovic. Let's get to
- 0:19Speaker 3: some stocks on the move. Here to help us with
- 0:21Speaker 3: that is Avalon Pronew. She's Bloomberg News Equities reporter. She
- 0:25Speaker 3: is in the house, and we're going to start off
- 0:27Speaker 3: with a postmarket name.
- 0:29Speaker 4: We sure are pre pre market name, Yes, Mission Produce.
- 0:32Speaker 4: That's ticker AVO currently unfor love avocados.
- 0:38Speaker 1: I know, go ahead, up.
- 0:39Speaker 4: I mean, who doesn't love avocados. It seems as if
- 0:42Speaker 4: the investors don't really love. It's currently slighting about five
- 0:45Speaker 4: point five percent in post market trading. That's after the
- 0:47Speaker 4: avocado supplier reported adjusted earnings per share for the second
- 0:51Speaker 4: quarter that missed expectations. Perhaps more importantly, it's saying that
- 0:55Speaker 4: it's expecting avocado prices to be down about fifteen percent
- 0:58Speaker 4: next quarter. Year of a year, since Harvard season looks
- 1:01Speaker 4: to be very plentiful this year.
- 1:03Speaker 1: Listen, that's great news for someone like me who buys
- 1:08Speaker 1: a lot of avocados. Yeah, that prices are going to
- 1:10Speaker 1: be done.
- 1:11Speaker 3: Yeah, that would be really nice. I agree. I agree.
- 1:13Speaker 3: We always have it like four or five in the fridge.
- 1:15Speaker 3: You do, I love me and avocado.
- 1:17Speaker 1: Very good for you too, I know exactly. Okay, So
- 1:19Speaker 1: fifteen lower then and goes with the prices not the stock.
- 1:23Speaker 3: Yeah, no, I'll take it. I'll take it. Hey, I
- 1:27Speaker 3: just want to mention one other after market, if we may.
- 1:30Speaker 3: Ticker is Empty and Veil Resorts, And we do see
- 1:33Speaker 3: this stock lower in the postmarket trade. It is down
- 1:38Speaker 3: as I bring it up on my Bloomberg down about
- 1:40Speaker 3: four and a half percent here. And that company, I
- 1:42Speaker 3: guess coming out was it earnings? Yeah, I guess it
- 1:46Speaker 3: was earnings third quarter EPs. That was a miss coming
- 1:50Speaker 3: in light third quarter net revenue was in line with
- 1:53Speaker 3: what the street was expecting. Total reported EBITDA was a
- 1:57Speaker 3: little bit higher than the street forecast, and all So
- 2:00Speaker 3: came out with his outlook.
- 2:01Speaker 1: Yeah, and here's the problem. Veil Resorts had a terrible
- 2:05Speaker 1: h well, the Western United States had a terrible tusky.
- 2:08Speaker 1: Meason Rob Katz was brought back in to turn the
- 2:11Speaker 1: company around. He was the longtime CEO at the company.
- 2:14Speaker 1: He retired a few years ago. They brought him back
- 2:16Speaker 1: to try to turn the company around after Kirsten Lynch
- 2:19Speaker 1: took over from him, and he's said a tough time
- 2:23Speaker 1: of it. Stocks up about three percent before today's results
- 2:25Speaker 1: going into this print. But like you said, Carol, the
- 2:30Speaker 1: company seen facing pressure from past sales and that fiscal
- 2:34Speaker 1: year net income outlook has been reduced.
- 2:35Speaker 3: Yeah, check this out Veil Resorts. He's fiscal year net
- 2:39Speaker 3: of one hundred and twenty eight million to one hundred
- 2:41Speaker 3: and sixty two million. It had seen one hundred and
- 2:43Speaker 3: forty four million to one hundred and ninety million. So
- 2:45Speaker 3: you know this avalon really well, Like that is quite
- 2:47Speaker 3: a haircut, all right. So that's a couple of names
- 2:49Speaker 3: in the postmarket on the move. What was really moving
- 2:53Speaker 3: to the upside today was Intel.
- 2:54Speaker 4: Yes, that's ticker I INTC had jumped eleven percent and
- 2:57Speaker 4: its best day in about a month after a media
- 3:00Speaker 4: report that Google placed an order for about three million
- 3:04Speaker 4: of Intel's AI chips. And this is obviously another step
- 3:08Speaker 4: in the right direction for Lebutan.
- 3:10Speaker 3: Yeah, I mean, man, that stuck is on fire. Yeah,
- 3:13Speaker 3: but now it has to make them right, It has
- 3:15Speaker 3: to make sure it can do this. I'm just saying
- 3:18Speaker 3: you're right.
- 3:19Speaker 1: Congratulations to the two of you who are shareholders in
- 3:21Speaker 1: the company. So you own to share, you own to share.
- 3:25Speaker 3: You own a share of Intel.
- 3:26Speaker 1: You know who else owns a lot of Intel Video? Yeah,
- 3:29Speaker 1: after that investment earlier this last year too.
- 3:32Speaker 2: Yeah, you're right.
- 3:32Speaker 1: Yeah, all right, So it's not just uh, it's not
- 3:34Speaker 1: just us.
- 3:35Speaker 3: All right, ready to tango.
- 3:37Speaker 1: Uh, let's talk tango.
- 3:38Speaker 2: Yeah.
- 3:39Speaker 4: Its Tango Therapeutics sets ticker TNGX surging fifty three percent
- 3:43Speaker 4: to end at a record high in the close. And
- 3:45Speaker 4: that's after a biotech released really positive data for its
- 3:48Speaker 4: experimental therapy to treat advanced pancreatic cancer. I feel like
- 3:51Speaker 4: this year we've heard a lot about pancreatic cancer, which
- 3:54Speaker 4: is really great for these patients. This combo drug did
- 3:57Speaker 4: show that it shrunk their like trunk to the different
- 4:00Speaker 4: tumors and patients, and Lyric writing that the data exceeds
- 4:03Speaker 4: expectations and really speaks for itself, especially on the efficacy.
- 4:07Speaker 4: So now Tango is planning to send that drug into
- 4:10Speaker 4: the next trial to have a late stage look at
- 4:14Speaker 4: what this drug potentially can do.
- 4:15Speaker 3: I have to say this is a real personal thing
- 4:17Speaker 3: for me. Having lost my mother to pancreatic cancer and
- 4:19Speaker 3: my dad lost my husband lost his father to it,
- 4:22Speaker 3: so you think it's a rare cancer. But as you
- 4:24Speaker 3: look at all the cancers that are out there, this
- 4:26Speaker 3: is one of those that has been really difficult in
- 4:29Speaker 3: terms of treatment because by the time you notice it,
- 4:32Speaker 3: it's usually so far progressed and there's not a lot
- 4:34Speaker 3: you can do. So certainly, as a family, something we're
- 4:37Speaker 3: watching to see what this does. But yeah, you're right,
- 4:40Speaker 3: we've heard a lot, but you know, you feel like
- 4:42Speaker 3: a lot of other cancers they figured out how to
- 4:44Speaker 3: deal with them, and this is one that is still
- 4:45Speaker 3: really tricky.
- 4:48Speaker 2: This stock mover's report from Bloomberg Radio. Check back with
- 4:52Speaker 2: us throughout the day for the latest roundup of companies
- 4:55Speaker 2: making news on Wall Street and for the latest market
- 4:58Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 5:02Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 5:06Speaker 2: the Bloomberg Business app.